Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mandated Part D Rebates Cannot Be Imposed Without Consequence To Beneficiaries, Holtz-Eakin Writes

This article was originally published in The Pink Sheet Daily

Executive Summary

In a Health Affairs Blog post, former CBO Director Douglas Holtz-Eakin takes issue with a recent article arguing that mandated Part D rebates would not lead to major Medicare premium increases or otherwise shift costs to Part D beneficiaries as well as employers.

You may also be interested in...



Reimbursement News, In Brief

Some patient groups ask Congress not to consider Medicaid-style rebates for dual-eligibles and low-income subsidy recipients in Medicare Part D; 72% of office-based physicians are using electronic health records; disparities in Medicaid EHR adoption, based on allocation of incentive payments, mirror those found in Medicare EHR adoption.

Orphan Indications In Medicare: Inspector General Will Examine Top-Selling Drugs

OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

Topics

UsernamePublicRestriction

Register

PS074794

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel